Robert S. Benjamin, M.D.
Dr. Benjamin is the Chairman of the Sarcoma Medical Oncology Department at The University of Texas M. D. Anderson Cancer Center. Under Dr. Benjamin, the Sarcoma Center has become one of the premier treatment and research centers in the nation dedicated solely to the management of soft-tissue and bone tumors. His team at the Sarcoma Center offers a multidisciplinary approach to the disease, providing the expertise of medical, surgical and radiation oncologist as well as pathologists and rehabilitation therapists for the benefit of each patient.
Dr. Benjamin has led groundbreaking research that has become standard treatment in the case of sarcomas and many other cancers, including multimodality treatment of soft-tissue sarcoma. He pioneered continuous infusion of Adriamycin and demonstrated its decreased cardiac toxicity, combination chemotherapy as a limb salvage regimen and the use of metal prostheses to replace diseased bones. Dr. Benjamin is active with M. D. Anderson's Phase 1 Clinical Trials Program, exploring a wide range of new anti-cancer agents and approaches. He is among the most prolific writers at M. D. Anderson, authoring more than 300 scientific articles. He was awarded the 2008 Nobility in Science Award from the Sarcoma Foundation of America.
M.D. Anderson Cancer Center
The University of Texas M. D. Anderson Cancer Center is one of the nation's best comprehensive cancer centers. For six of the past eight years, M. D. Anderson has ranked No. 1 in cancer care in "America's Best Hospitals" survey published in U.S. News and World Report. M. D. Anderson is focused on research on causes, treatments, and prevention of cancer, with the stated mission of "Making Cancer History." In 2009, more than 11,000 patients participated in therapeutic clinical research exploring novel treatments, making it the largest program of its kind in the United States.